stock decline

Corcept Therapeutics faces securities class action after FDA rejected lead drug relacorilant. Stock plummeted 50.4%; lead plaintiff deadline set for April 21, 2026.

Snowflake stock fell 20% in 2026 despite bullish analyst ratings. Critics argue valuation remains elevated despite slowing growth and rising losses.

$BBAI crashes 21.4% in February after Q4 revenue miss. Q4 revenue of $27.3M fell $6M short of estimates with 37.7% YoY decline, raising questions about defense contract momentum.

Plug Power faces securities fraud lawsuit over allegedly false DOE loan claims. PLUG shareholders have until April 3, 2026 to file in class action.

KDDI faces fraud investigation after ¥246 billion ($1.7B) in fictitious subsidiary revenue discovered. Stock fell 11.4%.

Amazon shares plunged on $200B AI capex and declining free cash flow, but accelerating AWS growth and analyst price targets suggest significant upside ahead.

uniQure stock plunges 49% after FDA rejects gene therapy data for AMT-130, triggering securities fraud class action lawsuit for investors trading September-October 2025.

Corcept Therapeutics stock plummeted 50% after FDA rejected lead drug relacorilant. Investors allege prior misleading statements about approval likelihood.

Ardent Health faces securities fraud lawsuit over alleged failure to disclose collections problems. Stock fell 33% after November revelation of $43M revenue cut and $57.5M EBITDA guidance reduction.

BellRing Brands faces securities fraud lawsuit after 52% stock decline tied to undisclosed inventory issues and weak guidance, with investor deadline March 23, 2026.

$PYPL faces class action lawsuit over allegedly false revenue projections. Stock plunged 20% after disappointing earnings and guidance withdrawal in February 2026.

PROCEPT BioRobotics faces securities fraud investigation after missing Q4 2025 revenue and slashing 2026 guidance by $20-40 million, prompting 15% stock decline.

Walker & Dunlop crashed 19% after reporting adjusted EPS 81% below consensus. Law firm investigates potential securities fraud following February 26 earnings miss.

Canopy Growth stock has crashed 99% from $300 to under $2, posting weak financials and facing structural industry headwinds despite U.S. cannabis reclassification.

Canyon Capital exits $13M Acadia Healthcare stake as stock falls 22% amid goodwill impairment and elevated 4.0x leverage concerns.

Pomerantz LLP investigates Carvana ($CVNA) for alleged $1B earnings overstatement and undisclosed related-party dependence, triggering 14.17% stock decline.

ThredUp shares plummeted 24% after Q4 earnings beat revenue forecasts but revealed declining profitability and slower 2026 growth guidance, dampening investor enthusiasm.

On Holding stock fell 6.95% despite 35.6% sales growth and record 62.8% gross margins, due to 2026 guidance missing analyst expectations by 200 million Swiss francs.

Pomerantz Law Firm files class action against $KD over alleged securities fraud, triggered by SEC investigation, late filings, and executive departures.

$MDB tumbled 20.9% after beating Q4 earnings but projecting only 17% annual sales growth. Geopolitical tensions and market weakness compounded investor disappointment.